Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma, but prognosis is still unsatisfactory. Recently, hepatic arterial infusion chemotherapy (HAIC), and immune checkpoint inhibitors showed promising results for advanced hepatocellular carcinoma. Considering diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Min-Ke, Liang, Run-Bin, Zhao, Yang, Xu, Yu-Jie, Chen, Huan-Wei, Zhou, Yuan-Min, Lai, Zhi-Cheng, Xu, Li, Wei, Wei, Zhang, Yao-Jun, Chen, Min-Shan, Guo, Rong-Ping, Li, Qi-Jiong, Shi, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010824/
https://www.ncbi.nlm.nih.gov/pubmed/33854567
http://dx.doi.org/10.1177/17588359211002720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010824/
https://www.ncbi.nlm.nih.gov/pubmed/33854567
http://dx.doi.org/10.1177/17588359211002720

Ejemplares similares